The cells are absorbed into the bone marrow and reproduce and then move into the blood stream, about the same process as a bone marrow transplant and actually is an alternative treatment. The entire concept is to rebuild the body’s immune system to fight of cancer and other disorders. This is kind of nice that a non profit center independent blood center received approval of their product. The organization relies on many volunteers and has been around since 1964. BD
The FDA has approved an umbilical cord blood product -- its first -- for use in stem cell transplants.
The product, known as Hemacord, "is indicated for use in hematopoietic stem cell transplantation procedures in patients with disorders affecting the hematopoietic (blood-forming) system," the agency said in a statement.
That includes certain blood cancers as well as some inherited metabolic and immune system disorders.
Hemacord contains hematopoietic progenitor cells from human cord blood. A study published last year found that cord blood was comparable to bone marrow or peripheral blood progenitor cells in treating acute leukemia in adults, with similar effects on leukemia-free survival.
Hemacord is manufactured by the New York Blood Center, based in New York City.
0 comments :
Post a Comment